化疗联合生物免疫治疗应用于晚期前列腺癌临床研究  

Effect of chemotherapy combined with bioimmune therapy on clinical efficacy and survival of advanced prostate cancer

作　　者：王腾春[1] 高伟[1] 袁守娴[1] 栾秀华[1] Wang Tengchun;Guo Wei;Yuan Shouxian;et al.(Department of Urology,the second people＇s Hospital of Liaocheng , Liaocheng 252600, Chin)

机构地区：[1]聊城聊城市第二人民医院泌尿外科,山东252600

出　　处：《国际泌尿系统杂志》2018年第3期365-368,共4页International Journal of Urology and Nephrology

摘　　要：目的 探讨化疗联合生物免疫治疗应用于晚期前列腺癌的临床研究.方法 选取本院2013年9月至2016年3月收治的96例晚期前列腺癌患者作为研究对象.随机将其分为两组,对照组给予患者单纯化疗,观察组给予化疗联合生物免疫进行治疗.对比分析两组治疗方法治疗晚期前列腺癌的临床疗效以及免疫组织细胞反应.治疗4个月后,进行为期1年的随访,观察两组患者的死亡率、生存期、疾病进展期（time to disease progression,TTP）以及出现的不良反应.结果 经过治疗后,观察组的总有效率为87.5％ （42/48）,显著高于对照组的总有效率68.8％（33/48）,两组比较差异具有统计学意义（P〈0.05）;观察组治疗后患者的外T淋巴细胞亚群中总T淋巴细胞、T辅助细胞、T抑制细胞、自然杀伤细胞、自然杀伤T细胞明显高于对照组,两组比较差异具有统计学意义（P〈0.05）;经治疗后,进行为期1年的随访,观察组病死率低于对照组（16.7％、37.5％）,且生存期高于对照组[（36.6±5.4）、（20.7±7.2）个月]、TTP也明显高于对照组[（29.8±5.7）、（19.7±9.3）个月],两组比较差异具有统计学意义（P〈0.05）;观察组的不良反应率为明显低于观察组（22.9％、43.8％）,两组比较差异具有统计学意义（P〈0.05）.结论 化疗联合生物免疫治疗晚期前列腺癌效果显著,能有效提升免疫功能细胞活性,延长生存期、TTP,减少死亡率,降低不良反应发生率,提高患者治疗后的生存质量.Objective To investigate the effect of chemotherapy combined with biological immunotherapy on clinical efficacy and survival of advanced prostate cancer.Methods Ninety-six patients with advanced prostate cancer who were treated from September 2013 to March 2016 in our hospital were randomly divided into two groups.The control group was given chemotherapy alone,the observation group was given chemotherapy combined with biological immunity for treatment.The clinical efficacy and immunohistochemical response of patients with advanced prostate cancer were compared and analyzed.After 4 months of treatment,the patients were followed up for 1 year.The mortality,survival and time to disease progression （TTP） as well as the occurrence of adverse reactions of the two groups were observed.Results After treatment,the total effective rate of the observation group was 87.5% （42/48）,which was significantly higher than that of the control group [68.8% （33/48].There was significant difference between the two groups （P 〈 0.05）.The numbers of Tlymphocytes,T helper cells,Tsuppressor cells,natural killer cells and naturak killer T were significantly higher than that in the control group in the external T lymph.There was a significant difference between the two groups （P 〈 0.05）.After 1 year of follow-up,the mortality rate of the observation group was lower than that of the control group,and the survival time （36.6 ± 5.4） months was higher than that of the control group （20.7 ± 7.2） months,TTP of the observation group was higher than that of the control group [（29.8 ± 5.7） months vs.（19.7 ± 9.3） months] （P 〈 0.05）.The adverse reaction rate （22.9%） in the observation group was significantly lower than that in the observation group （43.8%）,and the difference between the two groups was statistically significant （P 〈 0.05）.Conclusions Chemotherapy combined with biological immunotherapy is effective in advanced prostate cancer,which can effectively enhance the activity of immune

关 键 词：前列腺肿瘤 抗肿瘤联合化疗方案 免疫疗法 

分 类 号：R737.25[医药卫生—肿瘤]